PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2022
CASE
AUTH/3629/4/22 Daiichi-Sankyo UK

Daiichi Sankyo disease awareness campaign with patient organisation: material treated as contract for services, not all public education certified (AUTH/3629/4/22)

Panel said Daiichi Sankyo’s patient-organisation β€œcholesterol test” campaign was a contract for services, making the company responsible for materials. Some public educational…

2022
CASE
AUTH/3637/4/22 Daiichi-Sankyo UK

Daiichi Sankyo: patient website found to promote Nustendi to Nilemdo patients (AUTH/3637/4/22)

A post-prescription patient website for Nilemdo/Nustendi was ruled to promote Nustendi to patients prescribed Nilemdo by highlighting ezetimibe’s mechanism of action, likely…

2021
CASE
Galapagos ⭐ Case of the Week

Galapagos: β€˜Strength of balance’ homepage claim for Jyseleca ruled ambiguous (breach Clause 6.1)

PMCPA found Galapagos’ Jyseleca website homepage banner β€˜Strength of balance’ was ambiguous and insufficiently explained, breaching Clause 6.1. β€˜Delivering breakthroughs…’ drew concern…

2022
CASE
AUTH/3689/8/22 CSL Vifor

CSL Vifor voluntary admission: Ferinject conference banners shown to UK HCPs without UK certification (AUTH/3689/8/22)

At ESC-HFA 2022, Ferinject banner ads ran on the congress site/Medscape and unintentionally reached UK HCPs for 60 days without certification by…

2022
CASE
AUTH/3687/8/22 AstraZeneca

AstraZeneca: UK employees’ LinkedIn β€˜likes’ treated as proactive dissemination of US Enhertu post (AUTH/3687/8/22)

Eight UK-based AstraZeneca employees β€˜liked’ a US LinkedIn post linking to an Enhertu press release. The PMCPA ruled this proactively disseminated promotional…

2022
CASE
AUTH/3683/8/22 AstraZeneca

AUTH/3683/8/22: Complainant v AstraZeneca β€” Trixeo prescribing summary card (No breach)

Complaint about Trixeo promotional claims (spacer use, lung deposition %, and missing Symbicort PI). PMCPA Panel found no breach of the 2021…

2021
CASE
GlaxoSmithKline

GSK at ERS 2022: COPD network meta-analysis slides ruled misleading; MSL presence on promo stand not proven promotional

At ERS 2022, GSK-sponsored symposium slides on a COPD network meta-analysis were ruled misleading/unsubstantiated (Clauses 6.1, 6.2, 5.1). Allegations about MSLs acting…

2023
CASE
AUTH/3748/2/23 Otsuka ⭐ Case of the Week

Otsuka Europe website: outdated partner statement ruled inaccurate (AUTH/3748/2/23)

Otsuka’s β€œTherapy Areas in Europe” webpage still referenced working with partner Akebia on CKD anaemia after the agreement ended. PMCPA ruled the…

2023
CASE
AUTH/3794/7/23 Merck Serono

Merck Serono fertility event: co-chairs’ consultancy contracts not signed before services began (AUTH/3794/7/23)

PMCPA found Merck Serono failed to maintain high standards after two event co-chairs’ consultancy agreements were not agreed/signed in advance of services.…

2023
CASE
AUTH/3779/6/23 Boehringer Ingelheim

AUTH/3779/6/23 & AUTH/3780/6/23: Ex-employee complaint about alliance promotional material approval process (BI/Lilly) – No breach

Ex-employee alleged BI/Lilly alliance PMAP SOP and training were not accessible/controlled and that β€œagreements outside PMAP” existed. Panel found allegations not evidenced;…

2024
CASE
AUTH/3870/1/24 AstraZeneca

AUTH/3870/1/24: Complainant v AstraZeneca β€” Allegations about clinical trial material (Out of scope)

PMCPA case AUTH/3870/1/24 against AstraZeneca concerned allegations about clinical trial material. The matter was found outwith the scope of the ABPI Code;…

2023
CASE
AUTH/3817/9/23 AstraZeneca

AUTH/3817/9/23: AstraZeneca SENTINEL Plus website and MART references β€” no breach

Complaint alleged MART references on AstraZeneca’s SENTINEL Plus HCP website indirectly promoted Symbicort and therefore needed PI and an AE reporting statement.…

2023
CASE
AUTH/3829/9/23 GlaxoSmithKline ⭐ Case of the Week

AUTH/3829/9/23: Complainant v GSK β€” event website sponsorship declaration (no breach)

Complaint alleged GSK sponsorship of an HCP event wasn’t disclosed on the homepage or registration pages. Panel found sponsorship was sufficiently clear…

2023
CASE
AUTH/3856/11/23 Idorsia

PMCPA AUTH/3856/11/23: Complainant v Idorsia (Quviviq) β€” β€˜chronic insomnia’ wording in GP website ads (No breach)

Two Idorsia banner ads for Quviviq used the term β€œchronic insomnia”. Complaint alleged off-licence promotion vs SmPC. Panel found authoritative definitions aligned…

2024
CASE
AUTH/3888/4/24 Pfizer

Pfizer: Covid-19 vaccine Phase 3 efficacy tweets ruled promotional pre-authorisation and in breach of undertaking (AUTH/3888/4/24)

Pfizer UK’s 2020 Twitter thread on Phase 3 Covid-19 vaccine results (plus linked BioNTech content and press release) was ruled promotional before…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training